HLB starts Phase 3 clinical trials for ophthalmic disease treatment in US

South Korea's pharmaceutical company HLB Therapeutics Co. announced on Thursday that it has started patient administration of "RGN-259," a treatment for neurotrophic keratopathy, which is currently in development through its US subsidiary Regentry in Phase 3 clinical trials in the United States.

The company is developing RGN-259 as an eye-drop treatment for both dry eye syndrome and neurotrophic keratopathy.

The Phase 3 trial in the US involves administering RGN-259 to 70 patients for four weeks.

The company plans to conduct clinical trials of the same substance in Europe as well in order to shorten the approval period.

Write to Jae-Young Han at jyhan@hankyung.com